Members of the Trinity team recently researched adherence to clinic recommendations among patients with phenylketonuria. Review their findings on Molecular Genetics and Metabolism: http://bit.ly/2kAM9lE
Taking place January 9-13, one of our partners, Herman Sanchez, is at the industry event, which brings together thousands of investors and executives from around the world to see companies present their latest innovations, hoping to find their next partner or investor.
Trinity Partners today, in concert with the 35th Annual JP Morgan Healthcare Conference, has announced the findings of a white paper exploring the strategic decisions that successfully position a company for a maximized M&A exit. By examining the past ten years of biopharma M&A activity, Trinity has developed a framework that summaries the optimal path for private companies, taking into consideration major factors that inform valuations including financials, R&D portfolio, licensing opportunities, partnerships and more.
Download the whitepaper HERE
In a Q&A with Contract Pharma Editor Kristin Brooks, Trinity Founder and President John Corcoran discusses advances in science and technology, changing global healthcare markets and patient needs, along with the pharma and biopharmaceutical industry’s R&D efforts and evolving business models. Read the Q&A here: http://bit.ly/2iFDnzW
In the December issue of PM360, Partner Stephen Fleming discussed the life science industry’s biggest lessons learned in 2016, as well as potential challenges ahead in 2017. Stephen remarked on the importance of providing early-stage pharmaceutical/biotech companies with commercial support so they can independently develop and launch their drugs. He also discussed the importance of leveraging not only the commercial side, but also payer/access and patient perspectives throughout pre-launch work. In addition, Stephen highlighted challenges in value communication as an area of focus for the year ahead. Read Stephen’s complete commentary: http://bit.ly/2iERrw8
Trinity Partners President John Corcoran Discusses The Future of Drug Launches
John Corcoran, President of Trinity Partners, shared his expertise on the future of drug launches with FiercePharma. See the full article here: http://bit.ly/2h3DR1J
See her article “New Rules of Engagement: The Challenges Associated with Commercializing Biosimilars” here: http://bit.ly/2h3APKA
Boston, MA, December 1, 2016 – Trinity Partners, a global life sciences consulting firm, announced today that it has promoted two employees to the role of partner. Yogesh Soneji and Aparna Deshpande, formerly Principals at the firm, have been recognized for their long-standing dedication to Trinity and impact on the firm’s growth.
Deshpande joined Trinity in 2009 as the second employee in the Primary Market Research (PMR) group. Since then, she has helped to grow the group to over 20 people. Applying her deep experience in pharmaceutical market research, she has successfully raised customer engagement and grown relationships with numerous key clients, while helping colleagues develop and hone their skills.
“Aparna pioneered the PMR group here at Trinity, developing a framework of best practices and templates still used today,” said Neal Dunn, Partner at Trinity Partners. “Not only is she a trusted adviser and partner for her clients, she serves as a natural leader and mentor for her colleagues. Her dedication and hard work have resulted in an immeasurable impact on the PMR group.”
Soneji, who has been an employee at Trinity for 11 years, is an expert in global market assessments across a variety of therapeutic areas and industries. Throughout his time with Trinity he has leveraged his out-of-the-box thinking to drive best practices for device clients, advance innovation-related initiatives within the firm, and cultivate a practice of working with start-ups on exciting technologies.
“At Trinity, we pride ourselves in our ability to pair strategy and innovation in order to provide each of our clients with the most tailored and cutting-edge recommendations possible,” said Leslie Sandberg Orne, Senior Partner, Trinity Partners. “Yogi embodies that philosophy, regularly developing innovative frameworks and methodologies for strategic decision making. His ability to passionately approach difficult problems with critical thinking inspires everyone around him on a daily basis.”
These promotions, as well as 20+ others announced over the past few months, are a signal of Trinity’s ongoing growth. Based just outside of Boston, Trinity has additional offices in San Francisco, Princeton and New York City. The company is dedicated to fostering employee growth and development and implementing the tools and initiatives necessary to drive business success and provide a clear career path with proper development, training and mentorship. Trinity is currently celebrating its 20th year in business.
Trinity’s Ryan Million and Jillian Godfrey Scaife discuss the future of precision medicine and gene editing, respectively, in the November/December PharmaVOICE Year in Preview issue. View Ryan’s insight on precision medicine: http://bit.ly/2fZOamA. Read Jillian’s comments on gene therapy: http://bit.ly/2gaV0ZA.